ASGE Postgraduate Course at ACG 2022: Expanding the Scope of Fundamental and Advanced Endoscopy | October 2022-Point Counterpoint: Risk Stratification and Selection is Key for Barrett's Ablation

Point Counterpoint: Risk Stratification and Selection is Key for Barrett's Ablation

Video Transcription

Video Summary

In this video, Sachin Vani from the University of Colorado discusses risk stratification and selection for Barrett's ablation. He highlights the low risk of progression in patients with nondisplastic Barrett's esophagus, stating that only 0.25% of patients progress to esophageal adenocarcinoma. Vani argues against ablating all patients with nondisplastic Barrett's, citing the lack of level one evidence and the minimal reduction in an already low risk of cancer. He also discusses the challenges in managing patients with low-grade dysplasia and presents data from randomized control trials comparing surveillance to ablation. Vani emphasizes the need for a patient-centered approach and improved risk stratification tools.

Asset Subtitle

Sachin B. Wani, MD, FASGE

Keywords

risk stratification

Barrett's ablation

nondisplastic Barrett's esophagus

esophageal adenocarcinoma

low-grade dysplasia